Free Trial
OTCMKTS:ORINY

Orion Oyj 7/17/2023 Earnings Report

Orion Oyj logo
$31.70 -0.28 (-0.88%)
As of 05/2/2025 03:51 PM Eastern

Orion Oyj EPS Results

Actual EPS
$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Orion Oyj Revenue Results

Actual Revenue
$315.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Orion Oyj Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Orion Oyj Earnings Headlines

European Dividend Stocks To Consider In April 2025
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Orion Group Interim Report January–March 2025
See More Orion Oyj Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orion Oyj? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orion Oyj and other key companies, straight to your email.

About Orion Oyj

Orion Oyj (OTCMKTS:ORINY) develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

View Orion Oyj Profile

More Earnings Resources from MarketBeat